Expression of SART3 tumor-rejection antigen in gastric cancers

Fumihiko Niiya, Shinya Nishizaka, Kazuko Matsunaga, Kikuo Koufuji, Masaki Mori, Hitoshi Katai, Hideaki Yamana, Kyogo Itoh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We previously reported SART3 as a tumor-rejection antigen recognized by histocompatibility leukocyte antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs). In this study, we investigated the expression of the SART3 antigen in gastric cancers, as a candidate for use in specific immunotherapy. The SART3 antigen was detected in 9 of 10 (90%) gastric cancer cell lines, 35 of 52 (67.3%) gastric cancer tissues, and 0 of 20 non-tumorous gastric tissues. SART3-derived peptides corresponding to positions 109-118 and 315-323 induced HLA-A24-restricted and tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of gastric cancer patients. These peptide-induced CTLs recognized HLA-A24+ SART3+ gastric cancer cells, but not HLA-A24+ SART3- or HLA-A24- SART3+ gastric cancer cells. Therefore, the SART3 peptides could be useful in specific immunotherapy of gastric cancer patients.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalJapanese Journal of Cancer Research
Volume91
Issue number3
DOIs
Publication statusPublished - Mar 2000

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Expression of SART3 tumor-rejection antigen in gastric cancers'. Together they form a unique fingerprint.

  • Cite this

    Niiya, F., Nishizaka, S., Matsunaga, K., Koufuji, K., Mori, M., Katai, H., Yamana, H., & Itoh, K. (2000). Expression of SART3 tumor-rejection antigen in gastric cancers. Japanese Journal of Cancer Research, 91(3), 337-342. https://doi.org/10.1111/j.1349-7006.2000.tb00950.x